TY - JOUR T1 - Proteome-wide analysis of differentially-expressed SARS-CoV-2 antibodies in early COVID-19 infection JF - medRxiv DO - 10.1101/2020.04.14.20064535 SP - 2020.04.14.20064535 AU - Xiaomei Zhang AU - Xian Wu AU - Dan Wang AU - Minya Lu AU - Xin Hou AU - Hongye Wang AU - Te Liang AU - Jiayu Dai AU - Hu Duan AU - Yingchun Xu AU - Yongzhe Li AU - Xiaobo Yu Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/02/2020.04.14.20064535.abstract N2 - Rapid and accurate tests that detect IgM and IgG antibodies to SARS-CoV-2 proteins are essential in slowing the spread of COVID-19 by identifying patients who are infected with COVID-19. Using a SARS-CoV-2 proteome microarray developed in our lab, we comprehensively profiled both IgM and IgG antibodies in forty patients with early-stage COVID-19, influenza, or non-influenza who had similar symptoms. The results revealed that the SARS-CoV-2 N protein is not an ideal biomarker for COVID-19 diagnosis because of its low immunogenicity, thus tests that rely on this marker alone will have a high false negative rate. Our data further suggest that the S protein subunit 1 receptor binding domain (S1-RBD) might be the optimal antigen for IgM antibody detection, while the S protein extracellular domain (S1+S2ECD) would be the optimal antigen for both IgM and IgG antibody detection. Notably, the combination of all IgM and IgG biomarkers can identify 87% and 73.3% COVID-19 patients, respectively. Finally, the COVID-19-specific antibodies are significantly correlated with the clinical indices of viral infection and acute myocardial injury (p≤0.05). Our data may help understand the function of anti-SARS-CoV-2 antibodies and improve serology tests for rapid COVID-19 screening.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialZS-2303Funding Statementthe State Key Laboratory of Proteomics (SKLP-C202001, SKLP-O201703 and SKLP-K201505), the Beijing Municipal Education Commission, National Natural Science Foundation of China (81671618, 81871302, 81673040, 31870823), the National Program on Key Basic Research Project (2018YFA0507503, 2017YFC0906703 and 2018ZX09733003) and the CAMS Initiative for Innovative Medicine (2017-I2M-3-001 and 2017-I2M-B&R-01).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available upon the request of correspondering author. ER -